Supporting Drug Discovery as Well as Accurate and Efficient Cancer Diagnosis－Precision Medicine
Supporting Drug Discovery as Well as Accurate and Efficient Cancer Diagnosis
The significant side effects and ballooning costs of cancer treatment have become social issues. Precision medicine, in which medications are chosen for patients who have been grouped according to their physiological characteristics as analyzed based on genes and proteins, is gaining attention as a solution. Konica Minolta makes accurate and efficient cancer diagnosis a reality by combining its original technology for making visible specific proteins such as those found in cancer cells with technologies of two Konica Minolta Group companies in the US. In July 2018, Konica Minolta established Konica Minolta Precision Medicine Japan, Inc., a new company that will provide services in the field of precision medicine in Japan. In June 2019, Konica Minolta began joint R&D on next-generation comprehensive cancer gene panel testing with the University of Tokyo and the National Cancer Center Japan Research Institute. This has launched the company's full-scale participation in the effort to promote cancer genomic medicine in Japan. In addition, Group company Ambry Genetics Corporation, a major genetic diagnostic provider in the US, is engaged in intensive preparations to deliver a COVID-19 test (PCR test) to various organizations including the government. Going forward, Konica Minolta will continue to provide comprehensive services to pharmaceutical companies, academia, medical institutions, companies and employers.
Original technology differentiates cancer cells